John D Roberts, MD

Professor of Medicine (Medical Oncology); Medical Director, Adult Sickle Cell Program at Yale-New Haven Hospital York St Campus

Physician Biography

Dr Roberts primarily works in three areas: sickle cell disease, medical oncology, and human subjects protection. While Co-Director of the Virginia Commonwealth University Health System Adult Sickle Cell Program, he was a co-investigator in the landmark Pain in Sickle Cell Epidemiology Study. His cancer research focus is clinical trials. For almost 20 years he held various leadership positions in clinical and translational research at the VCU Massey Cancer Center, an NCI-designated cancer center. He has designed or conducted phase I, II, and III trials involving chemotherapy, biological response modifiers, and immunotherapy in diverse disease types. In 2012 he received the National Cancer Institute's Harry Hines Award for the Clinical Community Oncology Program Principal Investigator of the Year. He was Chair of the Virginia Commonwealth University IRB Panel A and is Co-Chair of the Yale Cancer IRB.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program | Prostate and Urologic Cancers Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Hospice & Palliative Medicine AB of Internal Medicine (2012)

Clinical Trials

Conditions Study Title
Prostate Bayer 16544: A randomized open-label phase IIa study evaluating the efficacy and safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide in subjects with castration-resistant prostate cancer (CRPC) who have bone metastases
Prostate SWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Prostate PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
ASG-22CE-13-2: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer that Express Nectin-4
Bladder A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies.
Bladder S1011: A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed At Time of Radial Cystectomy For Muscle Invasive Urothelial Cancer
Breast - Female, Colon, Hodgkin's Lymphoma, Lung, Melanoma, skin, Non-Hodgkin's Lymphoma, Ovary, Prostate An Open-Label, Dose-escalation/expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma

Edit this profile

Contact Info

John D Roberts, MD
Patient Care Locations
Yale Adult Sickle Cell ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 7th floor, Multispecialty

New Haven, CT 06511
Yale Prostate & Urologic Cancers ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th floor, Multispecialty Center

New Haven, CT 06511
Mailing Address
333 Cedar St/Medical Oncology
PO Box 208028

New Haven, Ct 06520-8028

Curriculum Vitae